In March 2020, Professor Benoit Deprez and Dr. Terence Beghyn, have decided to get involved in the fight against Covid19. The only way to respond quickly is to identify, among the molecules that can be used in humans, a molecule capable of reducing infection with the SARS-CoV2 virus.

Within the Task Force established on the Campus of the Institut Pasteur de Lille, our teams developed a screening assay (inspired by our technology) measuring the suffering of the infected cells. Then, this assay was used to test our collection of molecules approved in humans (TEELibrary).

Though such strategy are commonly used around the world, it is the uniqueness of the TEE Library that makes the difference. Indeed, it contains molecules approved in humans, either worldwide or within a few countries.

It is an active ingredient of a drug which is marketed in few countries that has attracted the attention of the Task Force. This medicine has not been identified by others and may be exclusive of the TEE Library. Its profile perfectly meets the specifications of the candidate drug against covid. Dr. Sandrine Bélouzard from the team of Dr. Jean Dubuisson’s team characterized the effect of our candidate in several models of SARS-CoV2 infection in high security laboratories.

Now all indicators are green. The antiviral effect will now be verified in a clinical trial. We hope to be able to initiate it by the end of the year and quickly have an impact on the epidemic. 5 millions euros are now required to get this milestone.